<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Coya JM</submitter><funding>Biotechnology and Biological Sciences Research Council</funding><pagination>927017</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9493720</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13</volume><pubmed_abstract>The exploration of therapies combining antimicrobial lung proteins and conventional antibiotics is important due to the growing problem of multidrug-resistant bacteria. The aim of this study was to investigate whether human SP-A and a recombinant trimeric fragment (rfhSP-A) have cooperative antimicrobial activity with antibiotics against pathogenic Gram-negative bacteria. We found that SP-A bound the cationic peptide polymyxin B (PMB) with an apparent dissociation constant (&lt;i>K&lt;/i> &lt;sub>D&lt;/sub>) of 0.32 ± 0.04 µM. SP-A showed synergistic microbicidal activity with polymyxin B and E, but not with other antibiotics, against three SP-A-resistant pathogenic bacteria: &lt;i>Klebsiella pneumoniae&lt;/i>, non-typable &lt;i>Haemophilus influenzae&lt;/i> (NTHi), and &lt;i>Pseudomonas aeruginosa&lt;/i>. SP-A was not</pubmed_abstract><journal>Frontiers in immunology</journal><pubmed_title>Cooperative action of SP-A and its trimeric recombinant fragment with polymyxins against Gram-negative respiratory bacteria.</pubmed_title><pmcid>PMC9493720</pmcid><funding_grant_id>BB/L007223/1</funding_grant_id><funding_grant_id>BB/T001976/1</funding_grant_id><pubmed_authors>Garcia-Fojeda B</pubmed_authors><pubmed_authors>Casals C</pubmed_authors><pubmed_authors>Kronqvist N</pubmed_authors><pubmed_authors>Fraile-Agreda V</pubmed_authors><pubmed_authors>de Tapia L</pubmed_authors><pubmed_authors>Saenz A</pubmed_authors><pubmed_authors>Bengoechea JA</pubmed_authors><pubmed_authors>Coya JM</pubmed_authors><pubmed_authors>Johansson J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Cooperative action of SP-A and its trimeric recombinant fragment with polymyxins against Gram-negative respiratory bacteria.</name><description>The exploration of therapies combining antimicrobial lung proteins and conventional antibiotics is important due to the growing problem of multidrug-resistant bacteria. The aim of this study was to investigate whether human SP-A and a recombinant trimeric fragment (rfhSP-A) have cooperative antimicrobial activity with antibiotics against pathogenic Gram-negative bacteria. We found that SP-A bound the cationic peptide polymyxin B (PMB) with an apparent dissociation constant (&lt;i>K&lt;/i> &lt;sub>D&lt;/sub>) of 0.32 ± 0.04 µM. SP-A showed synergistic microbicidal activity with polymyxin B and E, but not with other antibiotics, against three SP-A-resistant pathogenic bacteria: &lt;i>Klebsiella pneumoniae&lt;/i>, non-typable &lt;i>Haemophilus influenzae&lt;/i> (NTHi), and &lt;i>Pseudomonas aeruginosa&lt;/i>. SP-A was not</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2025-04-04T21:34:58.266Z</modification><creation>2025-04-04T21:34:58.266Z</creation></dates><accession>S-EPMC9493720</accession><cross_references><pubmed>36159837</pubmed><doi>10.3389/fimmu.2022.927017</doi></cross_references></HashMap>